Top 10 Companies in the (R)-3,3-Dimethyl-2-aminobutane (CAS 66228-31-7) Market (2026): Market Leaders Powering Global Chiral Chemistry

MARKET INSIGHTS

Global (R)-3,3-Dimethyl-2-aminobutane (CAS 66228-31-7) market was valued at USD 18.4 million in 2025. The market is projected to grow from USD 19.6 million in 2026 to USD 34.2 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(R)-3,3-Dimethyl-2-aminobutane (CAS 66228-31-7) is a chiral aliphatic amine characterized by its stereospecific (R)-configuration at the second carbon position. With the molecular formula C₆H₁₅N, this specialty chemical compound features a tert‑butyl group adjacent to the amino functionality, imparting notable steric bulk and conferring distinct reactivity profiles that make it particularly valuable as a chiral building block and resolving agent in asymmetric synthesis workflows.

The market is driven by rising demand from the pharmaceutical and fine chemicals sectors, where the compound serves as a key intermediate in the synthesis of enantiomerically pure active pharmaceutical ingredients (APIs). Furthermore, growing investment in stereoselective synthesis and the broader expansion of chiral chemistry applications are reinforcing demand.

(R)-3,3-Dimethyl-2-aminobutane (CAS 66228-31-7) Market – View in Detailed Research Report

---

1️⃣ 1. Capot Chemical Co., Ltd.

Headquarters: China
Key Offering: High‑purity chiral amines and API intermediates

Capot Chemical Co., Ltd. has established itself as a leading supplier of chiral building blocks, focusing on advanced asymmetric synthesis and resolution technologies. The company’s state‑of‑the‑art facilities enable the production of >99% ee (R)-3,3‑dimethyl‑2‑aminobutane at commercial scales, catering to pharmaceutical manufacturers and contract research organizations.

Sustainability & Growth Initiatives:

• Investment in green chemistry processes to reduce solvent usage
• Expansion of production capacity in China and India to meet global demand
• Strategic partnerships with major pharma companies for custom API intermediates

---

2️⃣ 2. Shanghai Hairui Chemical Technology Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Chiral ligands, asymmetric synthesis reagents, and specialty chemicals

Shanghai Hairui Chemical Technology is renowned for its asymmetric catalysis expertise and high‑purity chiral amines. The company supplies (R)-3,3‑dimethyl‑2‑aminobutane to leading pharmaceutical and fine‑chemical firms, supporting the development of next‑generation therapeutics.

Sustainability & Growth Initiatives:

• Implementation of continuous flow manufacturing to improve yield and reduce waste
• Development of enzyme‑based resolution processes for lower environmental impact
• Collaboration with research institutions to drive innovation in chiral chemistry

---

3️⃣ 3. Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: Pharmaceutical grade chiral intermediates and research‑grade reagents

Finetech Industry Limited specializes in the synthesis of high‑purity chiral amines for pharmaceutical and agrochemical applications. The company’s robust quality control ensures compliance with global regulatory standards.

Sustainability & Growth Initiatives:

• Adoption of renewable feedstocks for raw material sourcing
• Optimization of catalytic processes to increase energy efficiency
• Expansion of GMP‑compliant manufacturing facilities

---

4️⃣ 4. Biosynth Carbosynth

Headquarters: Basel, Switzerland
Key Offering: Custom high‑purity chiral amines via enzymatic resolution

Biosynth Carbosynth provides tailor‑made (R)-3,3‑dimethyl‑2‑aminobutane to boutique pharma and research labs, leveraging its proprietary enzymatic processes to deliver superior enantiomeric purity.

Sustainability & Growth Initiatives:

• Use of biodegradable enzymes for resolution processes
• Investment in process intensification to reduce carbon footprint
• Partnerships with academic institutions for catalyst development

---

5️⃣ 5. Enamine LLC

Headquarters: Kyiv, Ukraine
Key Offering: Enantiomerically pure chiral reagents and building blocks

Enamine LLC supplies (R)-3,3‑dimethyl‑2‑aminobutane to a global customer base, emphasizing strict quality control and rapid turnaround for R&D projects.

Sustainability & Growth Initiatives:

• Implementation of green solvent systems in synthesis
• Expansion of production capacity in Eastern Europe
• Collaboration with pharma giants for joint development projects

---

6️⃣ 6. PharmaBlock Sciences

Headquarters: Shanghai, China
Key Offering: High‑purity chiral intermediates and specialty chemicals

PharmaBlock Sciences focuses on delivering advanced chiral reagents for pharmaceutical and fine‑chemical applications, supporting the synthesis of complex APIs.

Sustainability & Growth Initiatives:

• Continuous improvement of catalytic efficiency to lower waste
• Investment in renewable energy for manufacturing sites
• Strategic alliances with global pharma R&D teams

---

7️⃣ 7. Aurum Pharmatech Limited

Headquarters: New Delhi, India
Key Offering: GMP‑compliant chiral intermediates and research reagents

Aurum Pharmatech Limited supplies high‑purity (R)-3,3‑dimethyl‑2‑aminobutane to pharmaceutical manufacturers and contract research organizations, emphasizing quality and regulatory compliance.

Sustainability & Growth Initiatives:

• Adoption of energy‑efficient manufacturing processes
• Use of locally sourced raw materials to reduce logistics footprint
• Expansion of production capacity to meet growing demand in Asia‑Pacific

---

8️⃣ 8. Cayman Chemical

Headquarters: Bethesda, USA
Key Offering: Analytical standards and high‑purity chiral reagents

Cayman Chemical provides reference standards and analytical support for (R)-3,3‑dimethyl‑2‑aminobutane, facilitating quality assurance for research and pharmaceutical applications.

Sustainability & Growth Initiatives:

• Implementation of ISO 9001 and ISO 14001 quality systems
• Use of green chemistry principles in laboratory‑scale synthesis
• Collaboration with academic and industrial partners for method development

---

9️⃣ 9. Tokyo Chemical Industry Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: High‑purity chiral intermediates and specialty chemicals

Tokyo Chemical Industry delivers (R)-3,3‑dimethyl‑2‑aminobutane to pharmaceutical and fine‑chemical customers, supporting advanced synthesis and R&D projects.

Sustainability & Growth Initiatives:

• Investment in advanced catalytic technologies for higher yield
• Reduction of hazardous waste through process optimization
• Partnerships with global pharma companies for custom solutions

---

🔟 10. J&K Scientific Ltd.

Headquarters: Shanghai, China
Key Offering: Research‑grade chiral amines and specialty reagents

J&K Scientific supplies (R)-3,3‑dimethyl‑2‑aminobutane to research institutions and contract manufacturers, focusing on high purity and rapid delivery.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks and green solvents
• Implementation of continuous flow processes to improve scalability
• Collaboration with academic research groups for new applications

---

Download FREE Sample Report: Download Sample

Get Full Report Here: Full Report

Outlook

Global demand for (R)-3,3‑dimethyl‑2‑aminobutane is expected to grow steadily, driven by the expanding pharmaceutical market, increasing investment in chiral synthesis technologies, and the emergence of antibody‑drug conjugates and other advanced therapeutics. The market is projected to reach USD 34.2 million by 2034, reflecting a robust CAGR of 7.2% over the forecast period.

Future Trends

Key future trends include:

• Continued advancement of biocatalytic and enzymatic processes, reducing production costs and environmental impact.
• Greater adoption of continuous flow and modular manufacturing platforms to enhance scalability and flexibility.
• Expansion of the chiral chemistry market into agrochemicals and advanced materials, leveraging the unique reactivity of (R)-3,3‑dimethyl‑2‑aminobutane.
• Increased focus on sustainability, with a shift toward renewable feedstocks and greener solvents.
• Strategic collaborations between fine‑chemical suppliers and global pharma companies to accelerate product development and commercialization.